Systemic lupus erythematosus is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
It can be suspected when ≥2 organ systems are involved.
It is predominantly diagnosed in females of childbearing age, rarely diagnosed before 8 years old.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Majority of patients have arthralgia of the hand.
Psychosis as a manifestation of neuropsychiatric (NP) systemic lupus erythematosus occurs rarely, taking place after SLE onset and negatively affecting health status, a study reports. Short- and long-term outlook appears to be good for most patients, although vigilant follow-up is needed.
The addition of ustekinumab to standard-of-care (SOC) treatment resulted in improved outcomes in adults with systemic lupus erythematosus (SLE) whose disease activity persisted despite standard treatment, according to a phase II trial.
Patients with systemic lupus erythematosus on hydroxychloroquine fare better, having lower mortality rates compared with those not using the drug, a study has shown. This survival benefit is further enhanced by treatment adherence.
Hydroxychloroquine (HCQ) inhibits the differentiation of Th17 cells and production of interleukin 17 (IL-17) both in vitro and in patients with systemic lupus erythematosus (SLE), a recent study has shown.
The selective T cell costimulation modulator abatacept drives a rapid improvement in proteinuria, which leads to earlier, sustained complete response compared with placebo in patients with active class III or IV lupus nephritis, although the rate of complete response is similar between groups, suggests a study presented at the EULAR 2018 Congress.
Roshini Claire Anthony speaks with Dr Annie Law, a consultant at the Department of Rheumatology & Immunology, Singapore General Hospital, on how primary care physicians can help in the management of systemic lupus erythematosus (SLE).
Short- and long-term renal outcomes improve with early renin–angiotensin–aldosterone system (RAAS) blockade with renin–angiotensin system inhibitors (RASI) in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study.
Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus, offering an alternative to the B cell–depleting agent rituximab, according to a study.
It appears that the Patient Reported Outcomes Measurement Information System Global Health Short Form (PROMIS10), which requires less than 2 minutes to complete, is useable, reliable and can efficiently screen for impaired physical function, emotional distress and pain in outpatients with systemic lupus erythematosus (SLE), reports a study.
Use of potassium citrate and thiazides appears to improve health-related quality of life (HRQOL) among stone formers across all Wisconsin Stone Quality of Life (WISQOL) domains without increasing the likelihood of gastrointestinal complaints and fatigue or sexual complaints, respectively, reports a study.
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Eating high amounts of red and processed meat prior to a diagnosis of colorectal cancer appears to be associated with shorter survival time, although a possible weak association cannot be excluded, a study has shown.